Skip to main content

Table 2 Tuberculosis activity between ICIs and Non-ICIs treatment group

From: Impact of immune checkpoint inhibitors (ICIs) therapy on interferon-γ release assay (IGRA) and diagnostic value in non-small cell lung cancer (NSCLC) patients

 

ICIs Therapy

n = 26

Non-ICIs Therapy

n = 14

P value

Active tuberculosis

3

0

0.186

Latent infection

23

14

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us